Evaluating everolimus for the treatment of breast cancer.
Camille Moreau-BachelardMarie RobertCarole GourmelonEmmanuelle BourboulouxAnne PatsourisJean-Sébastien FrenelMario CamponePublished in: Expert opinion on pharmacotherapy (2023)
Everolimus is relevant in the management of HR-positive ABC. Because of its efficacy, acceptable tolerability and the absence of drugs that have shown a greater benefit, it remains a second-line treatment option in HR-positive, HER2 negative (score 0) patients without BRCA mutation or visceral crisis and can be discuss with fulvestrant in second line after CDK4-6i. It is likely that within 5 years this treatment will be replaced in second line HR-positive breast cancer by new emerging treatments: drug-conjugated antibodies, tyrosine kinase inhibitors or immunotherapy in combination with chemotherapy.
Keyphrases
- end stage renal disease
- public health
- positive breast cancer
- emergency department
- metabolic syndrome
- squamous cell carcinoma
- chronic kidney disease
- skeletal muscle
- newly diagnosed
- young adults
- cell cycle
- ejection fraction
- drug induced
- peritoneal dialysis
- patient reported
- locally advanced
- combination therapy
- double blind
- prognostic factors